Recommendations for prophylaxis and management of tuberculosis in patients treated with TNF-α antagonists;Zalecenia postȩpowania w zapobieganiu i leczeniu gruźlicy u chorych leczonych antagonistami TNF-α

Reumatologia

Volumn 46, Issue 2, 2008, Pages 51-54

  Kucharz, Eugeniusz J ^a,c   Korzeniewska Koseła, Maria ^b   Kotulska, Anna ^a  

^a la skiego Uniwersytetu Medycznego W Katowicach

^b I Klinika Instytutu Gru licy I Chorób P uc W Warszawie

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Antagonists; Rheumatoid arthritis; TNF ; Tuberculosis

Indexed keywords

EID: 44649141203     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Winthrop KL, Siegel JN, Jereb J, et al. Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum 2005; 52: 2968-2974.
2. Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 2006; 119: 639-646.
3. Malipeddi AS, Rajendran R, Kallarackal G. Disseminated tuberculosis after anti-TNF-α treatment. Lancet 2007; 369: 162.
4. Arend SM, Leyten EMS, Franken WP, et al. A patient with de novo tuberculosis during anti-tumor necrosis factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45: 1470-1475.
5. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before initiation of anti-TNF-α therapy. Swiss Med Wkly 2007; 137: 621-622.
6. Kucharz FJ. Reumatoidalne zapalenie stawów: problemy diagnostyczne i terapeutyczne. Twój Magazyn Rodzinny 2002; 5: 49-55.
7. Kucharz EJ. Zastosowanie leków biologicznych w leczeniu chorych na reumatoidalne zapalenie stawów lub spondyloartropatie seronegatywne. Terapia 2007; 15/12: 9-12.
8. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003; 168: 1153-1156.
9. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
10. Gruźlica i choroby układu oddechowego w Polsce w 2006 r. Szczuka I (red.). Instytut Gruźlicy i Chorób Płuc, Warszawa 2006.
11. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155.
12. Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 2004; 30: 257-270.
13. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1103.
14. Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 295-299.
15. Korzeniewska-Koseła M. Rozpoznawanie i leczenie gruźlicy płuc. Współpraca lekarza rodzinnego z pulmonologiem. Lekarz Rodzinny 2004; 7-8: 846-852.
16. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002; 47: 1860-1866.
17. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007; 131: 1898-1906.
18. rd ed. Informa Healthcare, USA 2006; 155-181.
19. rd ed. Informa Healthcare, USA 2006; 215-263.
20. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-805.